A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer. READ MORE
Research in Review
Researchers used Surveillance, Epidemiology, and End Results registry data to review the costs associated with treatment plans consistent with NCCN guidelines.
A study recently published in Cancer found that women with newly diagnosed epithelial ovarian cancer taking beta-blockers had a more than 5-month increase in median overall survival compared with women not taking the drugs.
Fewer than 50% of eligible patients with debulked Stage 3 ovarian cancer treated at NCCN centers have received the treatment most recommended by NCCN guidelines.